PRESS RELEASE: VaxEquity and CPI Announce Innovate UK Grant to Accelerate Next Generation RNA Vaccines and Therapeutics

VaxEquity and CPI, the UK’s leading independent technology innovation centre, today announce a grant of approximately £700K from Innovate UK
June 2023
back

Cambridge, England, 5 June 2023 – VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform, and CPI, the UK’s leading independent technology innovation centre, today announce a grant of approximately £700K from Innovate UK. The grant will fund a collaborative project to advance the manufacturing process for RNA vaccines and therapeutics.

The project will test optimised conditions for scalability in the manufacturing of saRNA with plans to progress a candidate influenza vaccine rapidly into clinical trials. Flu is responsible for approximately 11,000 deaths each year in England and hospitalises many more[1].

Dr Tim Sparey, Managing Director at VaxEquity, said: “The potential of nucleic acids as vaccines and therapeutics is only just being realised. This powerful collaboration with CPI, fuelled by Innovate UK, starts with a giant step forward in scaling the manufacturing of a novel saRNA influenza vaccine. With our combined skill and capabilities, we plan to proceed into preclinical and clinical development to bring the world real benefit in the fight against flu. This collaboration will identify, establish, and protect an optimised process for saRNA manufacture which should open up the global horizon to many future vaccine and therapeutics.”

Brendan Fish, Director of Biologics & RNA Centre of Excellence at the CPI said: “We are delighted to be teaming up with RNA experts at VaxEquity to help ensure the promise of the post-pandemic push for global RNA vaccines is fulfilled. Through use of our RNA Centre of Excellence we will identify key factors in saRNA manufacturing to fine-tune and accelerate the process of saRNA transcription in batch processes, pioneering the path to the more efficient production of future saRNA vaccines.”

  1. https://www.gov.uk/government/news/record-numbers-offered-flu-vaccine-as-those-with-flu-and-covid-19-more-likely-to-die


ENDS


Media contacts:

Centre for Process Innovation

Eddie Steinson

Senior Press Officer

Eddie.Steinson@uk-cpi.com

About Centre for Process Innovation (CPI)

We catalyse the adoption of advanced technologies and manufacturing solutions to benefit people, places and our planet.

CPI connects the dots within the innovation ecosystem to make great ideas and inventions a reality to benefit people, places and planet. We’re a pioneering social enterprise that accelerates the development, scale-up and commercialisation of deep tech and sustainable manufacturing solutions. Through our incredible innovation experts and infrastructure, we look beyond the obvious to transform healthcare and drive towards a sustainable future.

As a trusted partner of industry, academia, government, and the investment community, we’re the catalyst for delivering smart AgriFoodTech, energy storage, HealthTech, materials, and pharma innovations. We believe by working together we can build a better collective future, and as part of the High Value Manufacturing Catapult, we facilitate access to world-class organisations to deliver transformation across industries.

Creating lasting global impact from the North of England and Scotland, we invest in people and disruptive technologies to invigorate economies, create circular supply chains and make our world a better place. Let’s innovate together: uk-cpi.com

Media contacts

Kerri Leach (VaxEquity)

kerri.leach@vaxequity.com

Katja Stout (Scius Communications)

katja@sciuscommunications.com

Daniel Gooch (Scius Communications)

daniel@sciuscommunications.com

About VaxEquity

VaxEquity is a UK biotechnology company developing next generation self-amplifying RNA and mRNA therapeutics and vaccines. Our proprietary RNA platform is designed to modulate the innate immune response to enable higher and longer protein expression allowing lower doses and expanding the potential of RNA for therapeutics as well as vaccines.

VaxEquity was founded in 2020 by Imperial College London’s Professor Robin Shattock, and specialist life sciences investor Morningside, and is led by a world class team who are RNA pioneers. The Company is based in Cambridge, UK, and is collaborating with AstraZeneca to progress its platform across multiple disease areas.


To learn more about VaxEquity please visit www.vaxequity.com and follow our LinkedIn.

Get in touch

Thank you for your message

We have recieved your message and will get back to your shortly.